Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ANTX with free AI briefings, catalyst countdowns, and dilution alerts.

ANTX · AN2 Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$80.2M Cash on Hand
36.7mo Cash Runway
Follow ANTX by email Get an email when ANTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ANTX, unsubscribe in one click. Privacy

📣 What ANTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Epetraborole MAC Lung Disease Phase 2/3 · NCT05327803 Terminated
AN2-502998 Healthy Volunteers Phase 1 · NCT07024589 Completed
Moxifloxacin Healthy Volunteers Phase 1 · NCT05995444 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ANTX holds $80.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.6M/quarter from operations, an estimated runway of 36.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 39 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANTX files for a raise →

👥 Who Owns ANTX

Insiders 11.5% Other 5%+ holders 13.4% Institutions (107 holders) 75.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
Commodore Capital LP Institution (13G, 5%+) 3,879,705 10.22% 2026-09-30
Coastlands Capital LP Institution (13G, 5%+) 3,803,851 10.03% 2026-09-30
Vivo Opportunity Fund Holdings, L.P. 5%+ holder (13G) 2,864,346 7.55% 2026-03-10
Eric Easom
Chief Executive Officer, Director · +967,149 options
Insider 2,409,486 6.35% 2026-09-30
Millennium Management LLC 5%+ holder (13G) 2,237,102 5.90% 2026-03-06
Robin Shane Readnour
Director · +64,866 options
Insider 633,842 1.67% 2026-09-09
Kabeer Aziz
Director · +64,866 options
Insider 439,113 1.16% 2026-10-12
Joshua M Eizen
Chief Operating Officer and Chief Legal · +242,150 options
Insider 207,546 0.55% 2026-11-05
Joseph S Zakrzewski
Director · +134,103 options
Insider 145,538 0.38% 2026-08-14
Sanjay Chanda
Chief Development Officer · +242,615 options
Insider 118,823 0.31% 2026-02-20
Lucy Day
Chief Financial Officer · +298,965 options
Insider 118,363 0.31% 2026-02-20
Cameron C. III Trenor
Chief Medical Officer · +233,333 options
Insider 116,667 0.31% 2026-09-15

Share count 37,943,650 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ANTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.